Synapse

← Cancer Drug Resistance

Papers in Cancer Drug Resistance

Page 9 · newest first

  1. Overcome cancer drug resistance by targeting epigenetic modifications of centrosomeCancer Drug Resistance · 2019
  2. Molecular mechanisms of enzalutamide resistance in prostate cancerCancer Drug Resistance · 2019
  3. Somatic pharmacogenomics of gastrointestinal stromal tumorCancer Drug Resistance · 2019
  4. Alkylating anticancer agents and their relations to microRNAsCancer Drug Resistance · 2019
  5. PARP inhibitors: clinical development, emerging differences, and the current therapeutic issuesCancer Drug Resistance · 2019
  6. MicroRNAs in neuroblastoma tumorigenesis, therapy resistance, and disease evolutionCancer Drug Resistance · 2019
  7. Resistance to anti-tubulin agents: From vinca alkaloids to epothilonesCancer Drug Resistance · 2019
  8. Lipid metabolic reprogramming as an emerging mechanism of resistance to kinase inhibitors in breast cancerCancer Drug Resistance · 2019
  9. Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeuticsCancer Drug Resistance · 2019
  10. Entrapment of DNA topoisomerase-DNA complexes by nucleotide/nucleoside analogsCancer Drug Resistance · 2019
  11. Mitochondrial determinants of chemoresistanceCancer Drug Resistance · 2019
  12. The effects of growth hormone on therapy resistance in cancerCancer Drug Resistance · 2019
  13. Long non-coding RNAs regulation of therapeutic resistanceCancer Drug Resistance · 2019
  14. Targeting MYCN and ALK in resistant and relapsing neuroblastomaCancer Drug Resistance · 2019
  15. The bone marrow microenvironment as a mediator of chemoresistance in acute lymphoblastic leukemiaCancer Drug Resistance · 2019
  16. Cancer stem cells in neuroblastoma therapy resistanceCancer Drug Resistance · 2019
  17. Pharmacogenetics implementation in the clinics: information and guidelines for germline variantsCancer Drug Resistance · 2019
  18. How to conjugate the stemness marker ALDH1A1 with tumor angiogenesis, progression, and drug resistanceCancer Drug Resistance · 2019
  19. The importance of epithelial-mesenchymal transition and autophagy in cancer drug resistanceCancer Drug Resistance · 2019
  20. Use of MRI, metabolomic, and genomic biomarkers to identify mechanisms of chemoresistance in gliomaCancer Drug Resistance · 2019
  21. Pharmacogenetics of thiopurinesCancer Drug Resistance · 2019
  22. The role of exosomal microRNAs; focus on clinical applications in breast cancerCancer Drug Resistance · 2019
  23. Pharmacogenetics implementation in the clinics: information and guidelines for germline variantsCancer Drug Resistance · 2019
  24. Pharmacogenetic and pharmacogenomic discovery strategiesCancer Drug Resistance · 2019
  25. Liquid biopsies in myeloid malignanciesCancer Drug Resistance · 2019
  26. MicroRNAs and cancer drug resistance: over two thousand characters in search of a roleCancer Drug Resistance · 2019
  27. Exosomal lncRNAs: the newest promising liquid biopsyCancer Drug Resistance · 2019
  28. The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunitiesCancer Drug Resistance · 2019
  29. Role of circulating tumor cell spheroids in drug resistanceCancer Drug Resistance · 2019
  30. Insights into breast cancer phenotying through molecular omics approaches and therapy responseCancer Drug Resistance · 2019
  31. Emerging targets in cancer drug resistanceCancer Drug Resistance · 2019
  32. Regulation of ABCB1 activity by microRNA-200c and microRNA-203a in breast cancer cells: the quest for microRNAs’ involvement in cancer drug resistanceCancer Drug Resistance · 2019
  33. Pharmacogenetics of asparaginase in acute lymphoblastic leukemiaCancer Drug Resistance · 2019
  34. Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumorsCancer Drug Resistance · 2019
  35. Circulating non-coding RNAs in recurrent and metastatic ovarian cancerCancer Drug Resistance · 2019
  36. Involvement of SNX1 in regulating EGFR endocytosis in a gefitinib-resistant NSCLC cell linesCancer Drug Resistance · 2019
  37. Mechanism of resistance to immune checkpoint inhibitorsCancer Drug Resistance · 2019
  38. Network rewiring, adaptive resistance and combating strategies in breast cancerCancer Drug Resistance · 2019
  39. Drug-adapted cancer cell lines as preclinical models of acquired resistanceCancer Drug Resistance · 2019
  40. Germline variants in cancer therapyCancer Drug Resistance · 2019
  41. Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapyCancer Drug Resistance · 2019
  42. Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenaseCancer Drug Resistance · 2019
  43. Relationship between ovarian cancer stem cells, epithelial mesenchymal transition and tumour recurrenceCancer Drug Resistance · 2019
  44. Targeting the “undruggable” RAS - new strategies - new hope?Cancer Drug Resistance · 2019
  45. In search of effective therapies to overcome resistance to Temozolomide in brain tumoursCancer Drug Resistance · 2019
  46. Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncologyCancer Drug Resistance · 2019
  47. Colorectal cancer stem cells properties and features: evidence of interleukin-8 involvementCancer Drug Resistance · 2019
  48. Components of the human-specific, p53-mediated “kill switch” tumor suppression mechanism are usurped by human tumors, creating the possibility of therapeutic exploitationCancer Drug Resistance · 2019
  49. Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adductsCancer Drug Resistance · 2019
  50. The use of pharmacogenetics to increase the safety of colorectal cancer patients treatedwith fluoropyrimidinesCancer Drug Resistance · 2019